← Back to Home

Oral Alzheimer’s Drug Candidate MNA-001 Shows Signals of TREM2 Target Engagement in Phase 1 Trial

Muna reported that MNA-001 entered volunteers’ cerebrospinal fluid and drove changes in target-related markers. This provides early human evidence for a strategy to modulate immune cells in the brain, but whether it can protect patients’ cognitive function remains a question for the next stage of trials.

By SURL BioNews

For immune cells in the brain to help treat Alzheimer’s disease, a drug must first reach the central nervous system and then demonstrate that it can affect the intended biological pathway. On October 21, Muna Therapeutics reported signals of both in a Phase 1 trial of its oral small-molecule candidate MNA-001, providing a basis for subsequent patient trials. There is currently no evidence that it can improve memory or slow disease progression.

MNA-001 targets TREM2, an important regulatory receptor on microglia. Microglia help clear cellular debris, process abnormal proteins and regulate inflammation, while certain genetic variants that weaken TREM2 function are associated with an increased risk of Alzheimer’s disease. According to the company, the drug is designed to stabilize signaling-capable TREM2 on the cell surface, thereby supporting sustained pathway activation.

The randomized, double-blind, placebo-controlled trial tested single and multiple ascending doses in young volunteers and also included an older cohort. The company said no serious adverse events were reported, no participants withdrew because of adverse events, and most adverse events were mild. Plasma drug exposure increased proportionally with dose, and pharmacokinetic profiles were similar in younger and older participants.

A key clue to target engagement came from soluble TREM2 in cerebrospinal fluid and plasma: its concentrations declined as the administered dose increased, with the response tending to plateau within a well-tolerated exposure range. The company interprets this as biomarker evidence of target engagement. Drug exposure in cerebrospinal fluid also supports MNA-001’s ability to enter the central nervous system.

Exploratory analyses went a step further to examine downstream biological responses. After repeated dosing in older volunteers, some cerebrospinal fluid markers associated with microglial activity, innate immunity and neuronal stress shifted toward levels observed in younger participants. However, markers approaching those of the younger group cannot be directly interpreted as brain rejuvenation, nor can they support an inference that patients’ cognitive function will improve.

The data disclosed so far still have clear limitations. The announcement did not provide participant numbers, complete data for each dose group, the magnitude of marker changes or statistical analyses, making it difficult to assess the consistency and clinical significance of the responses. Phase 1 tolerability results are also insufficient to establish long-term safety. The material published by BioSpace and PR Newswire came from the same company press release and does not constitute two independent validations.

Muna plans to launch a Phase 2 trial in early 2027, comparing MNA-001 with placebo in patients with early Alzheimer’s disease and combining cognitive assessments with biomarkers of disease progression to examine treatment effects. The central question for the next step is whether the biological activity observed in volunteers can translate into benefits that patients can perceive and that can withstand testing in a controlled trial.

References

  1. Muna Therapeutics via BioSpace
  2. Muna Therapeutics
  3. Muna Therapeutics via PR Newswire